At Senti Bio, we are a clinical-stage company that has integrated our Gene Circuit technology into several of our pipeline product candidates.
| Product Candidates | Target | Application | Preclinical | Early Stage Clinical | Late Stage Clinical | Collaborator |
|---|---|---|---|---|---|---|
| Wholly Owned Gene Circuit-Enhanced CAR Cell Therapy Programs for Oncology | ||||||
| SENTI-202 | CD33 and/or FLT3 | AML, MDS and other blood cancers | ||||
| SENTI‑301A/ | GPC3 | HCC and other solid tumors |  | |||
| Collaboration Programs | ||||||
| Multiple Gene Therapy Programs | Undisclosed | Eye, CNS and liver diseases |  | |||
| Multiple iPSC Cell Therapy Programs | Undisclosed | Regenerative medicine |  | |||
| Preclinical | Early Stage Clinical | Late Stage Clinical |
Product Candidates: SENTI-202 Target: CD33 and/or FLT3 Application: AML, MDS and other blood cancers | ||
Product Candidates: SENTI‑301A/ Target: GPC3 Application: HCC and other solid tumors | ||
| Preclinical | Early Stage Clinical | Late Stage Clinical |
Product Candidates: Multiple Gene Therapy Programs Target: Undisclosed Application: Eye, CNS and liver diseases | ||
Product Candidates: Multiple iPSC Cell Therapy Programs Target: Undisclosed Application: Regenerative medicine | ||
- Collaboration with Celest for clinical development to treat solid tumors in China, with an option to expand to Hong Kong, Macao, and Taiwan
- SN301A utilizes the same Gene Circuit as SENTI-301A and refers to the CAR-NK product manufactured by Celest in China